Assessing of Artificial Intelligence-based Software Platform for Diabetic Retinopathy Screening

Recruiting now

Conditions studied: Diabetic Retinopathy

In brief

To examine the potential for the detection of diabetic retinopathy (DR) using the artificial intelligence (AI)-based software platform Retina-AI.

Key facts

Study ID

NCT06879834

Run by

The Filatov Institute of Eye Diseases and Tissue Therapy

People needed

200

Starts

2024-11-02

Expected to finish

2025-12-01

Last updated by the study team

2025-03-17

Who can join

Age: 18 and older, up to 90. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Documented diagnosis of diabetes mellitus by definition.
• Understanding of the Study and willingness and ability to sign informed consent
• Patient age 18 or above
• Diagnostic for diabetes: 4a) Type 1 diabetes of a lest 5 years of evolution; or 4b) Type 2 diabetes

You may not qualify if…

• 1. Patients under 18 years of age; 2. Failure to give informed consent; 3. Presence of retinal diseases - acquired disease: age-related macular degeneration (AMD), occlusion of retinal vessels (ORV), etc.; birth defects: coloboma of choroid or optic nerve disc, etc.; hereditary diseases: retinitis pigmentosa, angioid streaks of the retina, etc.
• A patient who has already undergone treatment (surgery, laser, etc.) for any disease of the retina: age-related macular degeneration (AMD), retinal vascular occlusion (ARV), etc. These patients should be excluded or allocated to a separate group.

Where it is running

• The Filatov Institute of Eye Diseases and Tissue Therapy — Odesa, Ukraine (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.